Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Korlym (Mifepristone) for Treatment of Endogenous Cushing’s Syndrome

Drug Name (Brand / Generic)

Korlym / mifepristone

Developed by

Corcept Therapeutics

Therapy Class

Cortisol receptor blocker

Product Description

Glucocorticoid antagonist

Current Indication

Endogenous Cushing’s syndrome

Market Sector

Endocrinology

Development Status

Approved in the US
Expand
Close
Close
Close

Go Top